Jason Raleigh Nunn - Net Worth and Insider Trading

Jason Raleigh Nunn Net Worth

The estimated net worth of Jason Raleigh Nunn is at least $64 Million dollars as of 2024-11-13. Jason Raleigh Nunn is the Director of Zenas BioPharma Inc and owns about 3,056,801 shares of Zenas BioPharma Inc (ZBIO) stock worth over $64 Million. Details can be seen in Jason Raleigh Nunn's Latest Holdings Summary section.

Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Jason Raleigh Nunn has not made any transactions after 2024-09-16 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.

GuruFocus Premium Membership
30 Years of Financial Data on One Screen
Unlimited Filters in All-in-One Stock Screener
Exclusive Earnings Calls & Stock Analysis
Customizable Stock Dashboard
Real-Time Insider Trading Alerts
8,000+ Institutional Investors’ 13F Holdings
Excel & Google Sheets Integration
Downloadable Data
Quick Customer Support
And Much More...

Transaction Summary of Jason Raleigh Nunn

To

Jason Raleigh Nunn Insider Ownership Reports

Based on ownership reports from SEC filings, as the reporting owner, Jason Raleigh Nunn owns 5 companies in total, including Regulus Therapeutics Inc (RGLS) , Trevena Inc (TRVN) , and Dermira Inc (DERM) among others .

Click here to see the complete history of Jason Raleigh Nunn’s form 4 insider trades.

Insider Ownership Summary of Jason Raleigh Nunn

Ticker Comapny Transaction Date Type of Owner
RGLS Regulus Therapeutics Inc 2019-06-06 director
TRVN Trevena Inc 2022-06-09 director
DERM Dermira Inc 2020-02-20 director
LIMIT LIMIT 2015-05-22 director
LIMIT LIMIT 2009-01-30 director

Jason Raleigh Nunn Latest Holdings Summary

Jason Raleigh Nunn currently owns a total of 1 stock. Jason Raleigh Nunn owns 3,056,801 shares of Zenas BioPharma Inc (ZBIO) as of September 16, 2024, with a value of $64 Million.

Latest Holdings of Jason Raleigh Nunn

Ticker Comapny Latest Transaction Date Shares Owned Current Price ($) Current Value ($)
ZBIO Zenas BioPharma Inc 2024-09-16 3,056,801 20.82 63,642,597

Holding Weightings of Jason Raleigh Nunn


Jason Raleigh Nunn Form 4 Trading Tracker

According to the SEC Form 4 filings, Jason Raleigh Nunn has made a total of 1 transactions in Zenas BioPharma Inc (ZBIO) over the past 5 years, including 1 buys and 0 sells. The most-recent trade in Zenas BioPharma Inc is the acquisition of 882,352 shares on September 16, 2024, which cost Jason Raleigh Nunn around $15 Million.

Insider Trading History of Jason Raleigh Nunn

No transactions are available. GuruFocus only tracks and displays the purchase and sale of non-derivative security in open market or private transactions from SEC filings with the transaction code of P or S.
Total 0
  • 1
Only the transactions in Open Market or Private Sale at the market prices are included. Other transactions such as conversion of derivative security or exercise of options are not included. Insiders are limited to only officers and/or directors of the company.

Jason Raleigh Nunn Trading Performance

GuruFocus tracks the stock performance after each of Jason Raleigh Nunn's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Jason Raleigh Nunn is %. GuruFocus also compares Jason Raleigh Nunn's trading performance to market benchmark return within the same time period. The performance of stocks bought by Jason Raleigh Nunn within 3 months outperforms times out of transactions in total compared to the return of S&P 500 within the same period.

You can select different timeframes to see how Jason Raleigh Nunn's insider trading performs compared to the benchmark.

Please note GuruFocus will not track the insiders’ transaction performance if he/she does not have buying transactions.

Performance of Jason Raleigh Nunn

Average Return

No transaction record over 1 Year.

Outperforming Transactions

No transaction record over 1 Year.
Each transaction is measured over a period and compared to .
1 Month 3 Months 6 Months 1 Year 2 Years 3 Years
Return(%) 8.46 LIMIT LIMIT LIMIT LIMIT LIMIT
Relative Return to S&P 500(%) 4.74 LIMIT LIMIT LIMIT LIMIT LIMIT

Jason Raleigh Nunn Ownership Network

Ownership Network List of Jason Raleigh Nunn

No Data

Ownership Network Relation of Jason Raleigh Nunn

Insider Network Chart

Jason Raleigh Nunn Owned Company Details

What does Regulus Therapeutics Inc do?

Who are the key executives at Regulus Therapeutics Inc?

Jason Raleigh Nunn is the director of Regulus Therapeutics Inc. Other key executives at Regulus Therapeutics Inc include Sr. VP & General Counsel Christopher Ray Aker , Chief Operating Officer Joseph P Hagan , and Chief Financial Officer Crispina Calsada .

Regulus Therapeutics Inc (RGLS) Insider Trades Summary

Over the past 18 months, Jason Raleigh Nunn made no insider transaction in Regulus Therapeutics Inc (RGLS). Other recent insider transactions involving Regulus Therapeutics Inc (RGLS) include a net sale of 14,580 shares made by Joseph P Hagan , a net sale of 5,468 shares made by Crispina Calsada , and a net sale of 5,468 shares made by Christopher Ray Aker .

In summary, during the past 3 months, insiders sold 0 shares of Regulus Therapeutics Inc (RGLS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 25,516 shares of Regulus Therapeutics Inc (RGLS) were sold and 4,000 shares were bought by its insiders, resulting in a net sale of 21,516 shares.

Regulus Therapeutics Inc (RGLS)'s detailed insider trading history can be found in Insider Trading Tracker table.

To

Regulus Therapeutics Inc Insider Transactions

No Available Data

Jason Raleigh Nunn Mailing Address

Above is the net worth, insider trading, and ownership report for Jason Raleigh Nunn. You might contact Jason Raleigh Nunn via mailing address: 1119 St. Paul Street, Baltimore Md 21202.